These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30012197)

  • 61. Systematic computational identification of prognostic cytogenetic markers in neuroblastoma.
    Qin C; He X; Zhao Y; Tong CY; Zhu KY; Sun Y; Cheng C
    BMC Med Genomics; 2019 Dec; 12(1):192. PubMed ID: 31831008
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade.
    Mochizuki H; Thomas R; Moroff S; Breen M
    Chromosome Res; 2017 Jun; 25(2):129-143. PubMed ID: 28058543
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.
    Van Roy N; Van Der Linden M; Menten B; Dheedene A; Vandeputte C; Van Dorpe J; Laureys G; Renard M; Sante T; Lammens T; De Wilde B; Speleman F; De Preter K
    Clin Cancer Res; 2017 Oct; 23(20):6305-6314. PubMed ID: 28710315
    [No Abstract]   [Full Text] [Related]  

  • 64. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genomic Analysis Made It Possible to Identify Gene-Driver Alterations Covering the Time Window between Diagnosis of Neuroblastoma 4S and the Progression to Stage 4.
    Ognibene M; De Marco P; Parodi S; Meli M; Di Cataldo A; Zara F; Pezzolo A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742955
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
    Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
    BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
    Missiaglia E; Selfe J; Hamdi M; Williamson D; Schaaf G; Fang C; Koster J; Summersgill B; Messahel B; Versteeg R; Pritchard-Jones K; Kool M; Shipley J
    Genes Chromosomes Cancer; 2009 Jun; 48(6):455-67. PubMed ID: 19235922
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.
    Applebaum MA; Jha AR; Kao C; Hernandez KM; DeWane G; Salwen HR; Chlenski A; Dobratic M; Mariani CJ; Godley LA; Prabhakar N; White K; Stranger BE; Cohn SL
    Oncotarget; 2016 Nov; 7(47):76816-76826. PubMed ID: 27765905
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ArrayCGH-based classification of neuroblastoma into genomic subgroups.
    Michels E; Vandesompele J; De Preter K; Hoebeeck J; Vermeulen J; Schramm A; Molenaar JJ; Menten B; Marques B; Stallings RL; Combaret V; Devalck C; De Paepe A; Versteeg R; Eggert A; Laureys G; Van Roy N; Speleman F
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1098-108. PubMed ID: 17823929
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
    Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
    J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer.
    Brosens RP; Haan JC; Carvalho B; Rustenburg F; Grabsch H; Quirke P; Engel AF; Cuesta MA; Maughan N; Flens M; Meijer GA; Ylstra B
    J Pathol; 2010 Aug; 221(4):411-24. PubMed ID: 20593488
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
    Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
    Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Robust pathway-based multi-omics data integration using directed random walks for survival prediction in multiple cancer studies.
    Kim SY; Jeong HH; Kim J; Moon JH; Sohn KA
    Biol Direct; 2019 Apr; 14(1):8. PubMed ID: 31036036
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mutational dynamics between primary and relapse neuroblastomas.
    Schramm A; Köster J; Assenov Y; Althoff K; Peifer M; Mahlow E; Odersky A; Beisser D; Ernst C; Henssen AG; Stephan H; Schröder C; Heukamp L; Engesser A; Kahlert Y; Theissen J; Hero B; Roels F; Altmüller J; Nürnberg P; Astrahantseff K; Gloeckner C; De Preter K; Plass C; Lee S; Lode HN; Henrich KO; Gartlgruber M; Speleman F; Schmezer P; Westermann F; Rahmann S; Fischer M; Eggert A; Schulte JH
    Nat Genet; 2015 Aug; 47(8):872-7. PubMed ID: 26121086
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Novel Method for Identifying the Potential Cancer Driver Genes Based on Molecular Data Integration.
    Zhang W; Wang SL
    Biochem Genet; 2020 Feb; 58(1):16-39. PubMed ID: 31115714
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Meta-mining of copy number profiles of high-risk neuroblastoma tumors.
    Depuydt P; Koster J; Boeva V; Hocking TD; Speleman F; Schleiermacher G; De Preter K
    Sci Data; 2018 Oct; 5():180240. PubMed ID: 30375995
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.
    Bekhouche I; Finetti P; Adelaïde J; Ferrari A; Tarpin C; Charafe-Jauffret E; Charpin C; Houvenaeghel G; Jacquemier J; Bidaut G; Birnbaum D; Viens P; Chaffanet M; Bertucci F
    PLoS One; 2011 Feb; 6(2):e16950. PubMed ID: 21339811
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.
    Rombaut D; Chiu HS; Decaesteker B; Everaert C; Yigit N; Peltier A; Janoueix-Lerosey I; Bartenhagen C; Fischer M; Roberts S; D'Haene N; De Preter K; Speleman F; Denecker G; Sumazin P; Vandesompele J; Lefever S; Mestdagh P
    Sci Rep; 2019 Apr; 9(1):5685. PubMed ID: 30952905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.